# JenKem Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jenkem-technology-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.jenkem.com
- Latest round: Series B (Jun 8, 2016)
- Investors on record: 5

## About

Established in 2001 and based in Beijing, China, JenKem Technology Co., Ltd. operates as a pharmaceutical company dedicated to providing drug services ranging from reaction, purification, separation and final product analysis. It has sub-branch offices in Liaoning, Tianjin, and Shanghai. In 2008, it has obtained high-tech enterprise certification. In June 2016, the company closed seies B funding from new investors GTJA Innovation Investment and Tcc Capital. In August 2020, JenKem Technology Co., Ltd. was listed on the Shanghai Stock Exchange Sci-Tech Innovation Board.

The company focuses on small molecule antitumor drugs, active polyethylene glycol derivatives and other fields, and has a polyethylene glycol synthesis technology platform. Mainly aimed at users in the fields of medicine, chemical industry, materials and other fields, it provides a full set of services including drug reaction, purification, separation and final product analysis. It also provides polyethylene glycol (PEG) derivatives, PEG co-polymers, monodisperse PEGs, custom PEG derivative synthesis and PEGylation services.

The company generates revenue by providing drug services ranging from reaction, purification, separation and final product analysis.

## Funding rounds

- Series B, Jun 8, 2016 — GTJA Innovation Investment, TCC Capital
- Series A, Nov 2, 2015 — Tsinghua Innovation Ventures
- Angel, Nov 8, 2011 — CITIC Goldstone Fund Management, Jincan Investment

## Investors

- CITIC Goldstone Fund Management (https://capitalatlas.ai/funds/citic-goldstone-fund-management) — Angel
- Jincan Investment — Angel
- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Series A
- GTJA Innovation Investment (https://capitalatlas.ai/funds/gtja-innovation-investment) — Series B
- TCC Capital — Series B